Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D040921 | Stress Disorders, Traumatic NIH | 0.22 |
D013313 | Stress Disorders, Post-Traumatic NIH | 0.20 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The COVID-19 pandemic is a traumatic event which could lead to a greater risk of developing post-traumatic stress disorder, especially in cancer patients who feel more at risk of contracting the virus, and fear developing serious symptoms. The study's primary objective is to measure the presence of a potential post-traumatic stress disorder in cancer patients, and to assess the associated factors. The secondary objectives are to measure patients' anxiety, as well as their perception of both the management of their cancer care, and their fear of a cancer recurrence. It is a prospective, multi-centric study using self-assessing survey offered to cancer patients currently under ongoing care or treatment. The surveys will be sent by post at the beginning of the study, and again 6 months later. Expecting a participation rate of 40%, 4000 patients will be contacted, over a period of 3 months, in order to receive 1600 responses, and 640 responses 6 months later. Researching the factors associated with the appearance of post-traumatic stress could lead to better screening of patient disorders in highly anxiety-provoking crisis situations. As a result, it would lead to an improvement of their care, healthcare organization, and their follow-up in the case of a new epidemic or any other stressful event of this magnitude. Furthermore, promoting the patient's expression capabilities favors their implication in their care, and facilitates the development of health democracy.
Description: The factors associated with post traumatic stress, measured by the Impact of Event Scale Revisited scale
Measure: Factors associated with post-traumatic stress disorder Time: at inclusion and 6 months laterDescription: The measure of anxiety, measured by the State-Trait Anxiety Questionnaire
Measure: Measure of the patient's anxiety Time: at inclusion and 6 months later